Profile data is unavailable for this security.
About the company
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
- Revenue in EUR (TTM)1.02bn
- Net income in EUR24.35m
- Incorporated--
- Employees2.03k
- LocationAlmirall SARonda General Mitre, 151BARCELONA 08022SpainESP
- Phone+34 932913000
- Fax+34 932913681
- Websitehttps://www.almirall.es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon & Co | 5.34bn | 636.73m | 2.20bn | 10.00k | 3.45 | 4.74 | 2.48 | 0.4114 | 2.89 | 2.89 | 24.23 | 2.10 | 0.5026 | 2.05 | 4.19 | 629,400.00 | 5.99 | 11.52 | 7.54 | 14.94 | 57.18 | 62.30 | 11.92 | 20.24 | 1.15 | 2.60 | 0.9429 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Catalyst Pharmaceuticals Inc | 453.90m | 167.55m | 2.22bn | 181.00 | 13.67 | 3.30 | 11.13 | 4.90 | 1.57 | 1.57 | 4.25 | 6.51 | 0.6874 | 3.74 | 8.12 | 2,953,845.00 | 25.37 | 24.62 | 28.93 | 28.82 | 86.11 | 85.77 | 36.91 | 31.73 | 5.96 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
| Amneal Pharmaceuticals Inc | 2.40bn | -11.08m | 2.24bn | 8.10k | -- | -- | 9.66 | 0.9325 | -0.042 | -0.042 | 8.97 | -0.4201 | 0.8298 | 3.06 | 3.98 | 349,405.70 | 0.9505 | -2.12 | 1.35 | -2.68 | 36.69 | 35.94 | 1.15 | -3.47 | 0.845 | 1.45 | 1.02 | -- | 16.73 | 11.43 | -39.16 | -- | -5.10 | -- |
| Astrazeneca Pharma India Ltd | 170.43m | 11.49m | 2.26bn | 940.00 | 196.64 | 29.54 | 146.13 | 13.26 | 46.29 | 46.29 | 686.64 | 308.14 | 1.32 | 2.48 | 10.09 | -- | 8.92 | 11.06 | 15.07 | 18.24 | 43.89 | 50.74 | 6.74 | 9.43 | 1.13 | 146.55 | 0.0443 | 39.52 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Eris Lifesciences Ltd | 287.33m | 34.94m | 2.31bn | 3.56k | 66.11 | 8.14 | 33.68 | 8.03 | 25.81 | 25.81 | 212.30 | 209.63 | 0.4112 | 2.73 | 6.57 | 8,132,771.00 | 5.32 | 9.98 | 8.23 | 13.50 | 75.33 | 77.74 | 12.95 | 20.85 | 0.643 | 3.03 | 0.431 | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
| Almirall SA | 1.02bn | 24.35m | 2.31bn | 2.03k | 95.80 | 1.54 | 44.71 | 2.26 | 0.1123 | 0.1123 | 4.76 | 6.99 | 0.435 | 1.31 | 6.53 | 504,896.80 | 1.04 | 0.0824 | 1.19 | 0.0971 | 78.29 | 78.13 | 2.38 | 0.2141 | 1.75 | -- | 0.1854 | -- | 10.20 | 2.88 | 126.37 | -37.44 | 3.63 | -- |
| China Resources Dubl-Crne Phrmctl Co Ltd | 1.36bn | 203.59m | 2.33bn | 13.41k | 11.33 | 1.80 | -- | 1.71 | 1.67 | 1.67 | 11.13 | 10.51 | 0.6949 | 3.44 | 5.39 | 853,948.80 | 10.73 | 8.90 | 14.46 | 11.99 | 56.96 | 57.39 | 15.44 | 13.13 | 1.63 | -- | 0.0952 | 33.53 | -0.8711 | 3.63 | -2.19 | 9.06 | 21.41 | 9.15 |
| HUTCHMED (China) Ltd | 535.02m | 32.03m | 2.35bn | 1.81k | 73.52 | 3.65 | 54.88 | 4.40 | 0.3394 | 0.3394 | 5.67 | 6.84 | 0.4935 | 6.93 | 4.53 | 2,731,613.00 | 2.99 | -9.55 | 4.36 | -13.77 | 44.64 | 39.84 | 6.06 | -20.32 | 2.70 | -- | 0.1042 | -- | -24.80 | 25.20 | -62.56 | -- | 15.93 | -- |
| Emcure Pharmaceuticals Ltd | 784.06m | 67.66m | 2.36bn | 11.15k | 34.43 | 5.34 | 21.74 | 3.01 | 36.37 | 36.37 | 422.00 | 234.65 | 0.9846 | 1.82 | 4.07 | -- | 8.82 | 8.47 | 14.45 | 15.86 | 60.15 | 59.73 | 8.96 | 8.99 | 0.9834 | 6.36 | 0.1806 | -- | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
| Everest Medicines Ltd | 83.69m | -123.33m | 2.37bn | 665.00 | -- | 4.88 | -- | 28.37 | -3.55 | -3.55 | 2.41 | 13.75 | 0.1317 | 10.89 | 3.42 | 1,163,687.00 | -19.41 | -29.28 | -21.61 | -31.67 | 74.56 | -- | -147.36 | -1,040.86 | 2.52 | -- | 0.1238 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| Bora Pharmaceuticals Co Ltd | 612.68m | 175.10m | 2.41bn | 91.00 | 14.56 | 6.22 | 11.42 | 3.93 | 54.25 | 42.39 | 183.69 | 126.91 | 0.5385 | 3.94 | 2.99 | -- | 15.61 | 11.35 | 27.39 | 18.81 | 38.79 | 39.47 | 28.98 | 19.44 | 1.15 | -- | 0.5444 | 37.72 | 35.53 | 65.95 | 29.99 | 66.80 | -0.3363 | 74.57 |
Data as of Jul 04 2025. Currency figures normalised to Almirall SA's reporting currency: Euro EUR
10.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Oddo BHF Asset Management SASas of 30 May 2025 | 4.19m | 1.96% |
| The Vanguard Group, Inc.as of 04 Jun 2025 | 3.14m | 1.47% |
| Cobas Asset Management SGIIC SAas of 30 Apr 2025 | 2.85m | 1.34% |
| Santander Asset Management SA SGIICas of 31 Dec 2024 | 2.51m | 1.18% |
| Caixabank Asset Management SGIIC SAas of 31 Dec 2024 | 2.26m | 1.06% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.14m | 1.00% |
| Wellington Management Co. LLPas of 26 Jun 2025 | 1.92m | 0.90% |
| KBC Asset Management NVas of 31 Dec 2024 | 1.48m | 0.69% |
| Amundi Asset Management SASU (Investment Management)as of 04 Jun 2025 | 1.38m | 0.65% |
| Dimensional Fund Advisors LPas of 05 Jun 2025 | 1.06m | 0.50% |
More ▼
Data from 31 Dec 2024 - 25 Jun 2025Source: FactSet Research Systems Inc.
